Why the US Needs a Unified, Mission-Based Strategy for Health Innovation
The United States’ decades‑old linear research model—government funding, academic discovery, private commercialization—has driven breakthroughs like the Internet and vaccines, but today market‑driven incentives are skewing biomedical innovation toward high‑profit areas such as oncology. This has left critical fields like psychiatry under‑invested, while patent extensions inflate drug prices. Experts propose a mission‑based strategy anchored by a new advisory body that sets data‑driven health priorities, aligns funding, regulation and incentives, and expands public‑private partnerships. Such a coordinated framework aims to de‑risk high‑need research and ensure taxpayer‑funded discoveries benefit the broader public.
Scientists Find Hidden Brain Cells Helping Deadly Cancer Grow
Canadian researchers have uncovered that oligodendrocytes, a type of brain support cell, actively promote glioblastoma growth by signaling through the CCR5 receptor. In laboratory models, interrupting this communication dramatically slowed tumor expansion. The team also identified Maraviroc, an FDA‑approved HIV...
Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics
Pinnacle Medicines announced an $89 million Series B financing, bringing its total capital to $134 million, to advance an AI‑driven platform that designs orally bioavailable peptide drugs. The startup aims to launch its lead asthma and chronic obstructive pulmonary disease program in human...
Psilocybin Slows Down Human Reaction Times and Impairs Executive Function During the Acute Phase of Use
Researchers conducted a systematic review and multilevel meta‑analysis of 13 studies, finding that psilocybin dose‑dependently slows reaction times during its acute phase. While low to medium doses cause mild delays, high doses produce moderate to severe slowing, especially in basic...
Integrated Analysis Identifies Disulfidptosis Related Tumor Antigens and Molecular Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development
Researchers developed a disulfidptosis‑based framework for hepatocellular carcinoma (HCC) that combines molecular subtyping, mRNA vaccine design, and prognostic modeling. Analysis of TCGA‑LIHC and GEO data identified 32 disulfidptosis‑related genes that separate HCC into two subtypes with distinct survival, immune infiltration,...
Re: RSV Vaccination Programme Expanded to 3 Million More Older People
The UK health authorities have announced an expansion of the RSVpreF (Abrysvo) vaccination programme to include an additional three million adults aged 60 and older. Clinical trial data published in the New England Journal of Medicine confirm the vaccine’s ability...
U.S. Drug Tariffs Seen as Sparing Taiwan Prices, Supply
The United States has issued an executive order imposing up to 100% tariffs on patented drugs manufactured abroad, while offering a 20% rate for firms that relocate production to the U.S. Taiwan officials say the measure will not raise drug...
Real-World Safety of Second-Line Diabetes Drugs in Elderly
A 2026 Nature Communications study examined real‑world safety of second‑line diabetes drugs in patients 65 and older after metformin. Using electronic health records and claims data, the researchers compared sulfonylureas, DPP‑4 inhibitors, SGLT2 inhibitors and GLP‑1 agonists with propensity‑score matching....
Monday Morning Update 4/6/26
The Washington Post published a first‑person account of severe liver failure and a subsequent transplant after using a compounded GLP‑1 weight‑loss product. The story highlights the safety risks of off‑label, non‑FDA‑approved formulations that are increasingly marketed alongside AI‑driven GLP‑1 therapies....
Targetable Markers Define Antiprogestin-Resistant Breast Cancer
A new study in the British Journal of Cancer identifies a molecular triad—nuclear fibroblast growth factor‑2 (FGF2), androgen receptor (AR), and Wnt pathway activation—that defines a targetable subset of antiprogestin‑resistant luminal breast cancer. The researchers demonstrated that nuclear FGF2 cooperates...
Hong Kong: Advancing Smart Therapeutics, Translational MedTech
Hong Kong is positioning itself as a regional hub for biopharmaceutical innovation, focusing on advanced therapeutic products (ATPs) such as cell therapy. Invest Hong Kong is attracting mainland and international firms to set up R&D in the city, backed by...
Liver Specialist Amit Singal Joining Curve Biosciences
Amit Singal, a leading hepatology expert, has joined Curve Biosciences as chief medical officer. Singal currently serves as chief of hepatology at UT Southwestern Medical Center and authored the latest AASLD practice guidance on liver cirrhosis monitoring. Curve, based in San Mateo, leverages its...
Pharma Tariffs Pressuring Smaller Companies to Do MFN Deals
BioCentury’s website now outlines a comprehensive cookie framework that classifies cookies into five distinct groups: strictly necessary, functional, marketing, advertising, and analytics. Each category serves a specific purpose, from enabling authentication and core site functions to gathering anonymous usage metrics...
![[Correspondence] Suicidal Crisis: First Regulatory Approval of IV Racemic Ketamine](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/9ee5b606511aef98e3b5be5706cf97fd.webp)
[Correspondence] Suicidal Crisis: First Regulatory Approval of IV Racemic Ketamine
In March 2026 France became the first country to grant regulatory approval for intravenous racemic ketamine as a treatment for adult severe suicidal crisis. Clinical trials have shown that a single 0.5 mg/kg infusion over 40 minutes can blunt suicidal ideation...
FTC Lauds PBM, Insulin Efforts As Triumphs To Justify 2027 Budget Request
The Federal Trade Commission has submitted a FY2027 budget request of $426.7 million and 1,183 full‑time positions. The request emphasizes continuing its consumer‑protection agenda, notably the 2024 administrative complaint accusing pharmacy‑benefit managers (PBMs) of inflating insulin prices. It also funds an...
FDA Approves Extension of Eylea HD Dosing Intervals
The FDA has approved an extension of dosing intervals for Regeneron's Eylea HD, allowing injections as infrequently as every 20 weeks for patients with wet age‑related macular degeneration (AMD) and diabetic macular edema (DME). The label update incorporates two‑year efficacy and...
Resiliency in the Face of Volatility
Biotech markets are poised to sustain their outperformance as they navigate heightened geopolitical uncertainty. BioCentury’s Q2 2026 preview highlights strong follow‑on equity offerings and a robust M&A pipeline as primary catalysts. The sector’s resilience is underscored by more than $1 billion in...
Epigenetic Strategy Restores Tumor Suppressor in Acute Myeloid Leukemia Models
Researchers at The Jackson Laboratory have demonstrated that inhibiting KDM4 enzymes can reactivate the silenced tumor‑suppressor gene ZBTB7A in acute myeloid leukemia (AML) models. Using a novel FISHnCRISP platform that combines fluorescence in‑situ hybridization, flow cytometry and CRISPR editing, they...
Zanubrutinib Demonstrates Favorable Tolerability in R/R CLL/SLL
A systematic review and meta‑analysis of four trials involving 508 relapsed or refractory CLL/SLL patients found that zanubrutinib (Brukinsa) has low treatment‑discontinuation (7.2%) and atrial fibrillation rates (2.9%). While 98.5% of patients experienced at least one adverse event, only 67%...
Operationalizing Seamless Care Between Community and Academic Centers: Turab Mohammed, MD
Dr. Turab Mohammed, a hematologist‑oncologist at Novant Health, outlined how community systems can operationalize seamless collaboration with academic centers through dedicated care‑navigation teams and real‑time communication protocols. He emphasized early referral of high‑risk leukemia and lymphoma patients to preserve T‑cell...
Multi-Target Gene Therapy for Osteoarthritis: Dual-Axis Modeling and In Silico Validation
A computational study proposes a multi‑target gene therapy for osteoarthritis that combines anti‑inflammatory, anabolic, and catabolic‑blocking transgenes delivered via a dual‑vector AAV system. Network perturbation modeling shows the multi‑axis approach achieves an ECM Recovery Score of 76.2, markedly higher than...
Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines...
The FDA’s November 1, 2024 drug safety communication reports a preliminary review of suicidal thoughts and actions among patients using glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs). After analyzing adverse event reports, clinical trials and observational studies, regulators found no clear causal link,...
Scientists Map How the Body Traps 'Sleeping' Tuberculosis
Scientists at James Cook University used spatial transcriptomics to map where latent Mycobacterium tuberculosis resides within lymph nodes and bone marrow, revealing how the immune system contains the dormant bacteria. The study, published in Nature Communications, identified CD8⁺ T cells...
FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (Fezolinetant) for Hot Flashes Due to...
On December 16, 2024, the FDA issued a Boxed Warning for Veozah (fezolinetant), the first non‑hormonal drug approved for menopausal hot flashes, highlighting a rare but serious risk of liver injury. The agency now mandates baseline liver testing and monthly...
Serious Liver Injury Being Observed in Patients without Cirrhosis Taking Ocaliva (Obeticholic Acid) to Treat Primary Biliary Cholangitis
The FDA’s latest safety communication reveals that Ocaliva (obeticholic acid) is causing serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, including cases that required liver transplants or resulted in death. In a post‑market trial, 7 of 81...
FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis with the Multiple Sclerosis Medicine Glatiramer Acetate...
The FDA issued a new boxed warning for glatiramer acetate (Copaxone, Glatopa), highlighting a rare but potentially fatal anaphylactic reaction. Data from 1996‑2024 show 82 reported cases worldwide, including six deaths, with most events occurring within an hour of injection...
FDA Requires Warning About Rare but Severe Itching After Stopping Long-Term Use of Oral Allergy Medicines Cetirizine or Levocetirizine (Zyrtec,...
The FDA issued a drug safety communication warning that stopping long‑term use of oral antihistamines cetirizine (Zyrtec) or levocetirine (Xyzal) can trigger rare but severe itching (pruritus). Between April 2017 and July 2023, 209 cases—including 197 in the United States—were...
FDA Adds Warning About Serious Risk of Heat-Related Complications with Antinausea Patch Transderm Scōp (Scopolamine Transdermal System)
The FDA has issued a Drug Safety Communication adding a new warning to the Transderm Scōp scopolamine patch about serious heat‑related complications, including hyper‑temperature, hospitalization and death. The warning follows 13 reported cases worldwide—seven in the U.S.—with four hospitalizations and two...
FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger than 6 Years Taking Extended-Release Stimulants for ADHD
The FDA is requiring a uniform "Limitation of Use" label for all extended‑release stimulants used in ADHD treatment, warning that children under six years face higher drug exposure and a significant risk of weight loss. The agency’s analysis of clinical...
FDA Is Requiring Opioid Pain Medicine Manufacturers to Update Prescribing Information Regarding Long-Term Use
The FDA has mandated that manufacturers of extended‑release/long‑acting opioid analgesics update their prescribing information to reflect new post‑marketing study results. Two large PMR studies (3033‑1 prospective cohort and 3033‑2 retrospective cohort) found that roughly 22% of long‑term users develop opioid...
FDA Removes Risk Evaluation and Mitigation Strategy (REMS) Program for the Antipsychotic Drug Clozapine
The FDA announced that, effective June 13 2025, the risk evaluation and mitigation strategy (REMS) for clozapine is being eliminated. While the drug’s potential to cause severe neutropenia remains, the agency concluded that updated labeling and a new Medication Guide provide sufficient...
FDA to Recommend Additional, Earlier MRI Monitoring for Patients with Alzheimer’s Disease Taking Leqembi (Lecanemab)
On August 28, 2025 the FDA issued a drug‑safety communication recommending an additional magnetic resonance imaging (MRI) scan before the third infusion of Leqembi (lecanemab) for Alzheimer’s patients. The agency’s analysis identified 101 serious cases of amyloid‑related imaging abnormalities with...
The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again
The FDA approved Eli Lilly’s oral GLP‑1 tablet Foundayo (orforglipron) in April 2024, pricing it at $25 per month with insurance or $149 self‑pay. New pipeline candidates—including Eli Lilly’s triple‑agonist retatrutide, Novo Nordisk’s high‑dose Wegovy and CagriSema, and Amgen’s monthly‑dose MariTide—promise greater efficacy,...
Molecular End Points Poised to Transform Myeloma Drug Approval: Nicholas Richardson, DO, MPH
The FDA released draft guidance proposing minimal residual disease (MRD) negativity and complete response as primary endpoints for accelerated approval of multiple myeloma therapies. MRD is defined as fewer than one myeloma cell per million bone‑marrow cells, measured by flow...
Zenkuda Superior to Sham in Phase 3 Diabetic Retinopathy Study
Kodiak Sciences reported that its intravitreal biologic Zenkuda (tarocimab tedromer) outperformed sham in the phase 3 GLOW2 trial for diabetic retinopathy. At week 48, 62.5% of patients receiving Zenkuda achieved a two‑step or greater improvement on the Diabetic Retinopathy Severity Scale versus...
Revolution Medicines Initiates P-III (RASolute 303) Trial of Daraxonrasib in Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines has launched the global Phase III RASolute 303 trial to evaluate daraxonrasib, a direct RAS(ON) multi‑selective inhibitor, in previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The study tests the drug as monotherapy and alongside chemotherapy, with progression‑free survival and overall...
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech announced it will shut its Singapore mRNA manufacturing plant by the end of February 2027, ending a venture that began with a $355 million investment in 2022. The site, originally slated to create over 100 jobs and produce several hundred...
Python Blood Could Hold the Secret To Healthy Weight Loss
Researchers at the University of Colorado Boulder have identified a python‑derived metabolite, para‑tyramine‑O‑sulfate (pTOS), that spikes dramatically after the snakes eat and appears to suppress appetite. In mouse studies, high doses of pTOS triggered weight loss without the gastrointestinal side...
Henlius Receives the NMPA IND Clearance for HLX319 (Biosimilar, Phesgo)
Henlius has received IND clearance from China’s NMPA for HLX319, a biosimilar of Roche’s Phesgo that combines pertuzumab, trastuzumab and hyaluronidase for subcutaneous delivery. The product targets neoadjuvant, adjuvant and metastatic HER2‑positive breast cancer, mirroring Phesgo’s five‑to‑eight‑minute injection without weight‑based...
Superpower Partners with Grail to Add Galleri Cancer Screening
Superpower, a technology‑driven health benefits platform, announced a partnership with Grail to incorporate the Galleri multi‑cancer blood test into its member offerings. Galleri screens for more than 50 cancer types using DNA methylation signatures and has received FDA clearance for...
Annovis Wins US Patent for Buntanetap in Brain Infection Injuries
Annovis Bio has been granted a United States patent for its compound Buntanetap, specifically covering its use in treating brain infection‑related injuries. The patent expands the drug's previously explored Alzheimer’s indication to a novel therapeutic area. This intellectual‑property win bolsters...
Multipurpose Anti-Viral Pill May Treat Colds, Norovirus, Flu and Covid
Artificial intelligence flagged a long‑neglected breast‑cancer medication as a candidate to block multiple viruses, and subsequent animal studies confirmed it can inhibit coronaviruses, RSV, norovirus, influenza and hepatitis viruses. Model Medicines, a California biotech, is advancing the compound toward a...
Tirzepatide vs Semaglutide: Which One Burns More Fat?
Recent comparative studies indicate tirzepatide outperforms semaglutide in accelerating fat loss. Tirzepatide’s dual activation of GLP‑1 and GIP receptors delivers stronger appetite suppression, improved insulin sensitivity, and enhanced lipid metabolism, leading to higher average weight‑loss percentages. Semaglutide remains effective by...
Merck Initiates P-IIb/III (MALBEC) Trial of MK-8748 for Neovascular Age-Related Macular Degeneration
Merck has launched the pivotal Phase IIb/III MALBEC trial to evaluate MK‑8748 (Tiespectus/EYE201) in patients with neovascular age‑related macular degeneration (NVAMD). The study pits two intravitreal dose levels of the bispecific TIE2‑agonist/VEGF‑inhibitor against aflibercept 2 mg, beginning with quarterly injections for three...
FDB Launches MedProof MCP to Ground AI Agents in Clinical Drug Knowledge
First Databank (FDB) has released MedProof MCP, the first Model Context Protocol server designed to embed AI agents with its clinical‑grade drug database. The open‑source MCP standard lets large language models query trusted medication intelligence in real time, cutting integration...
Earendil Labs Begins Phase 2a Trial of Ulcerative Colitis Therapy
Earendil Labs has dosed the first patient in a Phase IIa, randomized, placebo‑controlled trial of its half‑life‑extended anti‑TL1A antibody HXN‑1001 for ulcerative colitis. The company also completed enrollment for the Phase I study in healthy volunteers in Australia, where single doses up...
Levothyroxine Shows No Benefit in Older Adults
A new systematic review in BMC Geriatrics finds that levothyroxine offers no measurable benefit for older adults with subclinical hypothyroidism. Patient‑reported quality‑of‑life, cognitive function, physical performance, and major cardiovascular events were unchanged compared with observation or placebo. The analysis also...
Machine Learning-Based Prediction of SARS-CoV-2 Bioactivity: Integrating IC50 Regression and Activity Classification Using Multi-Task Neural Networks
Researchers introduced an integrated machine‑learning framework to predict SARS‑CoV‑2 compound potency. The system combines an IC50 regression model, a binary activity classifier, and a multi‑task neural network that performs both tasks simultaneously. Incorporating ligand efficiency as a classification criterion, the...
Science Spotlight: Three Teams Converge on RNU2‑2 as Targetable for Neurodevelopmental Epilepsies
Three independent research teams reported in Nature Genetics that variants in the non‑coding RNA RNU2‑2 cause both a dominant neurodevelopmental epilepsy syndrome and a prevalent recessive childhood disorder with epilepsy. By analyzing overlapping international cohorts and shared genomic datasets, they...
Sunshine Biopharma Inc (SBFM) Q4 2025 Earnings Call Transcript
Sunshine Biopharma reported a $713 million cash balance and zero debt at year‑end, while GAAP operating expenses fell to $225 million, driven by lower stock‑based compensation. The company’s Biologics License Application for ivonesumab in EGFR‑mutant NSCLC was accepted by the FDA, with...